Glutathione injections can be administered in two ways: intravenously (IV) or through intramuscular (IM) injections
Additionally, a new GLP-1 candidate, pemvidutide, has recently shown weight reductions in a Phase 2 trial with a lower percentage of muscle loss compared to other GLP-1s
Randomized withdrawal trials and off-treatment extensions recorded substantial average weight regain after semaglutide or tirzepatide was withdrawn
Phase 3 trials across the broader TRIUMPH programme are projected to continue through 2025 and beyond, with regulatory submission timelines dependent on full data readouts
As glutathione levels decline due to age, stress, toxins, and lifestyle, the consequences can be far-reaching: fatigue, dull skin, poor immunity, and slower recovery all become more common